Theory of relativity Cutaneous February 17, 2023 Another RELATIVITY trial demonstrates the promise of adding the LAG-3 inhibitor relatlimab to nivolumab for metastatic melanoma, not only upfront,…
Checkpoint Cutaneous November 3, 2022 In case you’re not convinced, another retrospective study, this one looking at 203 patients receiving radiosurgery for 1388 melanoma brain…
Combo Cutaneous October 14, 2022 The SECOMBIT trial demonstrated relative good outcomes with any sequencing of combo ipilimumab/nivolumab and dual BRAF/MEK inhibition for metastatic BRAF-mutated…
Burn victim Cutaneous October 7, 2022 We have sad news for our fellow Southerners out there with Northern-European ancestry who filled their childhood summers with care-free…
Thinning out incidence Cutaneous April 12, 2022 There are no official recommendations for melanoma screening among the general population, as no strategy has proven worthwhile. The University…